UHS FY 2025 income before income taxes rose 32% to USD 1.97 billion

Reuters
02/26
UHS FY 2025 income before income taxes rose 32% to USD 1.97 billion

UHS reported FY 2025 net revenues of USD 17.4 billion (+9.7%) and income from operations of USD 2.0 billion, with net income of USD 1.5 billion and net income attributable to shareholders of USD 1.5 billion (+30%). FY 2025 interest expense, net was USD 156.1 million (-16%), and the effective tax rate was 23.4% (vs. 22.4%). By segment, acute care net revenues were USD 9.9 billion (+11.0%) and income before income taxes was USD 1.0 billion (+25.0%). Behavioral health net revenues were USD 7.4 billion (+8.0%) and income before income taxes was USD 1.5 billion (+7.7%). UHS said FY 2025 net revenues benefited from same-facility growth and contributions from two newly constructed acute care hospitals: West Henderson Hospital in Las Vegas (opened Q4 2024) and Cedar Hill Regional Medical Center in Washington, D.C. (opened Q2 2025), while Cedar Hill generated a FY 2025 pre-tax loss of USD 49 million. The company also recorded a USD 93 million unrealized pre-tax gain tied to a minority investment in a healthcare generative AI company, and highlighted ongoing exposure to Medicaid supplemental payment programs (FY 2025 aggregate net benefit of USD 1.339 billion) alongside expected future reductions under the One Big Beautiful Bill Act beginning with the 2028 state fiscal years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Universal Health Services Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-071676), on February 25, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10